---

---

positive   source : Www.biospace.com   

save search

---

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.24 -38.71% 32K |

n/a

| 1.3% | O: 0.0% H: 1.73% C: 1.3%
for set market

---

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
NVNO | $5.27 -4.18% -4.36% 100K |

Manufacturing

| 2.35% | O: 9.8% H: 0.0% C: -6.79%
symposium positive topline trial today

---

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K |

Health Technology

| 0.9% | O: 1.03% H: 0.72% C: -0.13%
positive treatment global for

---

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -0.97% | O: -0.11% H: 0.0% C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K |

Health Technology

| 3.97% | O: 5.49% H: 2.84% C: -0.65%
nbi-1065 positive for

---

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| 3.96% | O: -0.4% H: 3.01% C: 2.94%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| 2.2% | O: 0.83% H: 1.35% C: 1.2%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| 0.46% | O: -0.75% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 4.25% | O: 0.82% H: 0.0% C: 0.0%
first treatment for

---

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 2.36% | O: 0.75% H: 0.0% C: 0.0%
rinvoq positive cell results study

---

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.75 -1.6% -1.63% 66K |

Health Technology

| 34.67% | O: 5.41% H: 41.06% C: 29.66%
bb-301 first positive biopharma for trial opmd study

---

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.635 -6.63% -7.1% 180K |

| -19.55% | O: 9.85% H: 4.63% C: -18.04%
fda positive pharmaceuticals for technology response

---

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
ALKS | $24.66 1.65% 1.62% 1.7M |

Health Technology

| -5.63% | O: 4.48% H: 0.82% C: -2.05%
narcolepsy positive topline results study

---

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -1.07% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

---

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $12.0 0.25% 0.25% 190K |

n/a

| 7.06% | O: 0.36% H: 0.18% C: -2.76%
ocs-01 positive treatment for meeting trial results

---

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K |

Health Services

| -1.25% | O: 2.12% H: 4.35% C: 2.25%
bladder positive cancer trial

---

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K |

Health Technology

| -5.62% | O: -1.3% H: 0.7% C: 0.36%
pruritus positive livmarli

---

CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
CYDX | $0.41 -14.15% 290 |

n/a

| Email alert Add to watchlist
breast biomarker positive cancer diagnostics results study

---

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
PTPI | $0.635 -6.63% -7.1% 180K |

| Email alert Add to watchlist
positive pharmaceuticals results study

---

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 4.78% | O: -1.18% H: 0.34% C: -0.22%
breast her2 license cancer application negative

---

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K |

Health Technology

| -5.8% | O: 8.7% H: 3.33% C: -8.67%
ctim-76 application therapeutics

---

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
EQ | $1.8 4.65% 4.44% 110K |

Health Technology

| -22.51% | O: -1.73% H: 0.0% C: -7.05%
lupus positive topline study

---

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K |

Health Technology

| -10.61% | O: -2.27% H: 0.0% C: 0.0%
positive treatment results study

---

Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
TNON | $0.7101 5.89% 7.3K |

| -22.84% | O: 2.54% H: 1.98% C: -5.45%
first positive system medical results study

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---